Omnitrope 15 IU Cartridge

Manufacturer: Sandoz

Pharmaceutical name: Somatropin

Pack: 1 cartridge (15 IU (5mg/1.5ml))

Omnitrope is a synthetic version of human growth hormone (HGH) created by Sandoz Pharmaceuticals. HGH is a naturally occurring protein in the body that promotes the growth of bone and cartilage. Omnitrope is a recombinant protein, meaning it is manufactured in a laboratory and closely resembles natural HGH in structure. This FDA-approved product is user-friendly and offers a cost-effective treatment option for children with growth hormone deficiency. Omnitrope is available in packs of 5, with cartridges containing either 1.5ml/5mg (15iu) or 1.5ml/10mg (30iu).

 

In pediatrics, Omnitrope is prescribed for children experiencing growth failure due to growth hormone deficiency (GHD) and Prader-Willi syndrome (confirmed by genetic testing). It is also used to address growth failure in children born small for gestational age (SGA) who do not achieve catch-up growth by age 2, as well as for those with idiopathic short stature (short stature without a known cause) and girls with Turner Syndrome (who have only one X chromosome). For adults, Omnitrope treats both adult-onset and childhood-onset growth hormone deficiency.

 

Omnitrope is not suitable for children who: are experiencing acute critical illnesses, have respiratory failure, are diagnosed with cancer/active malignancy, suffer from active proliferative or non-proliferative diabetic retinopathy, have known hypersensitivity to somatropin, possess closed epiphyseal plates, are severely obese or have respiratory issues associated with Prader-Willi Syndrome, or have recently undergone trauma or surgery.

 

Before prescribing Omnitrope, physicians should be vigilant for the following: signs of upper airway obstruction and sleep apnea in children with Prader-Willi Syndrome; treatment should be halted if such symptoms occur; monitoring for neoplasm progression or recurrence in patients with existing tumors; childhood cancer survivors treated with somatropin are at increased risk for a second neoplasm, particularly meningiomas in those who received head radiation for their initial tumor; glucose levels should be checked in all patients, as the dosages of concurrent anti-hyperglycemic medications may need adjustment due to potential unmasking of diabetes; intracranial hypertension can occur and may be resolved by lowering the dose or stopping